



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger

Judith U. Kim Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Rae Lynn P. Guest

Daniel A. Klein Jason D. Eisenberg Michael D. Specht Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Ted J. Ebersole Laura A. Vogel Bryan S. Wade Shannon A. Carroll

Wesley W. Jones Matthew E. Kelley Michelle K. Holoubek Marsha A. Rose\*

Registered Patent Agents Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Christopher J. Walsh Liliana Di Nola-Baro Peter A. Socarras Jeffrey Mills Danielle L. Letting

Of Counsel Kenneth C. Bass III Marvin C. Guthrie

Admitted only in Maryland \* Admitted only in Virginia Practice Limited to Federal Agencies

February 6, 2006

WRITER'S DIRECT NUMBER: (202) 772-8529 INTERNET ADDRESS: LVOGEL@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Art Unit 1631

Mail Stop: Amendment

Re:

U.S. Utility Patent Application

Application No. 08/479,038; Filed: June 7, 1995

Supplemented Fibrin Matrix Delivery Systems (as amended)

Inventors:

DROHAN et al.

Our Ref:

1327.0440006/ELE/LAV

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover:

\$180.00 Submission of Information Disclosure Statement;

- 2. Tenth Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(d);
- 3. One (1) page of Form PTO/SB/08B listing two documents (AR85 and AS85); and
- 4. Copies of the two listed documents; and
- 5. Return postcard

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skaf.com

Commissioner for Patents February 6, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Laura A. Vogel

Attorney for Applicants Registration No. 55,702

LAV/rjv Enclosures

492893\_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DROHAN et al.

Appl. No.: 08/479,038

Filed: June 7, 1995

For: Supplemented Fibrin Matrix

Delivery Systems (as amended)

Confirmation No.: 7774

Art Unit:

1631

Examiner:

Marschel, A. H.

Atty. Docket: 1327.0440006/ELE/LAV

**Tenth Supplemental Information Disclosure Statement** 

Under 37 C.F.R. § 1.97(d)

Mail Stop: Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Tenth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Ninth Supplemental Information Disclosure Statement filed on August 15, 2005 in connection with the above-captioned application. Copies of documents AR85 and AS85 are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based

00000046 08479038

02/08/2006 HALI11

180,00 OP

01 FC:1806

on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Enclosed find our credit card payment form PTO-2038 in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Laura A. Vogel

Attorney for Applicants Registration No. 55,702

Date: Teb. 6,2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

487044v1

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	08/479,038
				Filing Date	June 7, 1995
				First Named Inventor	William N. DROHAN
				Art Unit	1631
				Examiner Name	Marschel, A. H.
Sheet	1	of	1	Attorney Docket Number	1327.0440006/ELE/LAV

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AR85	Kim, NH., et al., "Effect of Porcine Bone Morphogenetic Protein on Healing of Bone Defect in the Rabbit Radius," Yonsei Med. J. 33:54-63, Yonsei University (March 1992)	
-	AS85	Ney, A.L., et al., "Fibrin Glue-Antibiotic Suspension in the Prevention of Prosthetic Graft Infection," J. Trauma 30:1000-1006, The Williams & Wilkins Co. (August 1990)	
:			

487047v1

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.